View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
December 19, 2018

Anchiano starts Codex study for bladder cancer drug

Anchiano Therapeutics has commenced the Codex, a Phase ll trial examining the efficacy and safety of inodiftagene vixteplasmid (BC-819) for the treatment of patients with non-muscle-invasive bladder cancer (NMIBC).

Anchiano Therapeutics has commenced a Phase II Codex trial examining the efficacy and safety of inodiftagene vixteplasmid (BC-819) for the treatment of patients with non-muscle-invasive bladder cancer (NMIBC).

Inodiftagene vixteplasmid is a gene therapy and a recombinant DNA plasmid designed to direct the expression of a potent toxin specifically in malignant cells without affecting normal tissue.

The multicentre, open-label, single-arm trial aims to enrol 140 patients with NMIBC that have high-grade stage Ta or T1 papillary tumours or carcinoma in situ (CIS) and whose disease is unresponsive to bacillus calmette-guerin (BCG) therapy.

“BCG-unresponsive NMIBC represents an area of high unmet medical need with limited standard treatment options.”

Anchiano will administer 20mg of inodiftagene vixteplasmid as monotherapy via instillation into the urinary bladder for ten weeks, which will be followed by treatment every three weeks for up to two years or until disease recurrence.

The trial’s primary objective is complete response rate in patients with clinically isolated syndrome (CIS).

It is expected to observe patients with complete response for at least one year following the beginning of response.

Interim analysis will then be conducted on data from the first 35 CIS patients.

Anchiano Therapeutics chief medical officer Dr David Kerstein said: “BCG-unresponsive NMIBC represents an area of high unmet medical need with limited standard treatment options, outside of surgical removal of the bladder.

“NMIBC is a cancer that has been lacking in new therapies for two decades, and we are excited to embark on this important next step in the development of inodiftagene vixteplasmid.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena